American Heart Journal
Volume 158, Issue 1 , Pages 133-140 , July 2009

Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities

Received 19 October 2008 ,Accepted 30 April 2009.

References 

  1. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392–2397
  2. Gardner RS, Ozalp F, Murday AJ, et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003;24:1735–1743
  3. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014–1021
  4. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non–ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 2003;41:1264–1272
  5. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106:2913–2918
  6. de Lemos JA, Morrow DA. Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application?. Circulation. 2002;106:2868–2870
  7. Heeschen C, Hamm CW, Mitrovic V, et al. N-terminal pro–B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004;110:3206–3212
  8. Lindahl B, Lindback J, Jernberg T, et al. Serial analyses of N-terminal pro–B-type natriuretic peptide in patients with non–ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)–II substudy. J Am Coll Cardiol. 2005;45:533–541
  9. Morrow DA, de Lemos JA, Blazing MA, et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. Jama. 2005;294:2866–2871
  10. Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002;39:202–209
  11. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458
  12. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–1463
  13. Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004;44:335–339
  14. Silver MA, Maisel A, Yancy CW, et al. A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail. 2004;10:1–30
  15. Ang DS, Pringle SD, Struthers AD. The cardiovascular risk factor, left ventricular hypertrophy, is highly prevalent in stable, treated angina pectoris. Am J Hypertens. 2007;20:1029–1035
  16. Liao Y, Cooper RS, McGee DL, et al. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. Jama. 1995;273:1592–1597
  17. Ghali JK, Liao Y, Simmons B, et al. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med. 1992;117:831–836
  18. Conen D, Zeller A, Pfisterer M, et al. Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. Am J Cardiol. 2006;97:249–252
  19. Goetze JP, Christoffersen C, Perko M, et al. Increased cardiac BNP expression associated with myocardial ischemia. Faseb J. 2003;17:1105–1107
  20. Palazzuoli A, Gennari L, Calabria P, et al. Relation of plasma brain natriuretic peptide levels in non–ST-elevation coronary disease and preserved systolic function to number of narrowed coronary arteries. Am J Cardiol. 2005;96:1705–1710
  21. Sadanandan S, Cannon CP, Chekuri K, et al. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non–ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;44:564–568
  22. Rana BS, Davies JI, Band MM, et al. B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes. Heart. 2006;92:916–920
  23. Wong KY, McSwiggan S, Kennedy NS, et al. B-type natriuretic peptide identifies silent myocardial ischaemia in stroke survivors. Heart. 2006;92:487–489

PII: S0002-8703(09)00354-8

doi: 10.1016/j.ahj.2009.04.024

American Heart Journal
Volume 158, Issue 1 , Pages 133-140 , July 2009

Article Tools

* Image Usage & Resolution